Grant ID RP180530
Awarded On February 21, 2018
Title Hippo signaling in non-alcoholic fatty liver disease (NAFLD) and it progression to hepatocellular carcinoma
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Randy Johnson
Cancer Sites Gallbladder, Liver and Intrahepatic Bile Duct
Contracted Amount $821,669
Lay Summary

Liver cancer is the fifth most common malignancy and is the third cause of cancer related deaths world wide with poor clinical prognosis, especially when diagnosed at advanced stages. Liver cancer incidence is increasing, in part to major risk factors including non-alcoholic fatty liver disease and non-alcoholic steatohepatitis that is prevalent in Western populations, including the United States and especially in Texas. We have partnered with Ionis Pharmaceuticals to develop their unique technology to target molecules and pathways previously thought to be “undruggable” leading to effective targeted therapy in preclinical models for liver cancer. Ionis has demonstrated experience in achievin...

Read More